HRP20060127A2 - Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist - Google Patents

Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist

Info

Publication number
HRP20060127A2
HRP20060127A2 HR20060127A HRP20060127A HRP20060127A2 HR P20060127 A2 HRP20060127 A2 HR P20060127A2 HR 20060127 A HR20060127 A HR 20060127A HR P20060127 A HRP20060127 A HR P20060127A HR P20060127 A2 HRP20060127 A2 HR P20060127A2
Authority
HR
Croatia
Prior art keywords
arylindenopyridines
adenosine
receptor antagonist
pharmaceutical compositions
arylindenopyrimidines
Prior art date
Application number
HR20060127A
Other languages
English (en)
Inventor
Geoffrey
James
Kenneth
Original Assignee
Ortho-Mcneil Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical filed Critical Ortho-Mcneil Pharmaceutical
Publication of HRP20060127A2 publication Critical patent/HRP20060127A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Ovaj izum osigurava nove arilindenopiridine i arilindenopirimidine formula (I), (II), gdje su R1, R2, R3, R4 i X kao što je gore definirano i farmaceutski sastavi sadrže iste, korisne za liječenje poremećaja koji se poboljšavaju sa antagonističkim djelovanjem na adenozin A2a receptore. Ovaj izum također osigurava terapeutske i profilaktičke postupke koji primjenjuju tekuće spojeve i farmaceutske sastave.
HR20060127A 2003-10-03 2006-03-30 Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist HRP20060127A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/031471 WO2005042500A1 (en) 2003-10-03 2003-10-03 Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist

Publications (1)

Publication Number Publication Date
HRP20060127A2 true HRP20060127A2 (en) 2006-07-31

Family

ID=34548801

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20060127A HRP20060127A2 (en) 2003-10-03 2006-03-30 Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist

Country Status (22)

Country Link
EP (1) EP1673354B1 (hr)
JP (1) JP4725963B2 (hr)
CN (1) CN1878761A (hr)
AT (1) ATE429421T1 (hr)
AU (1) AU2003275430A1 (hr)
BR (1) BR0318521A (hr)
CA (1) CA2540686A1 (hr)
CY (1) CY1109808T1 (hr)
DE (1) DE60327375D1 (hr)
DK (1) DK1673354T3 (hr)
EA (1) EA200600688A1 (hr)
EC (1) ECSP066474A (hr)
ES (1) ES2326075T3 (hr)
HK (1) HK1091200A1 (hr)
HR (1) HRP20060127A2 (hr)
IL (1) IL174678A0 (hr)
IS (1) IS8377A (hr)
NO (1) NO20061981L (hr)
PT (1) PT1673354E (hr)
RS (1) RS20060237A (hr)
SI (1) SI1673354T1 (hr)
WO (1) WO2005042500A1 (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
CN101511190A (zh) 2006-07-11 2009-08-19 詹森药业有限公司 组胺h4受体的苯并呋喃并-和苯并噻吩并嘧啶调节剂
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
CN101835759A (zh) 2007-10-24 2010-09-15 詹森药业有限公司 芳基茚并嘧啶及其作为腺苷A2a受体拮抗剂的用途
PA8801401A1 (es) * 2007-10-25 2009-05-15 Janssen Pharmaceutica Nv Arilindenopirimidinas y su uso como adenosina a2a
US20100093763A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20110105493A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
US20110105492A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F ARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
US20110105494A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F Heteroaryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
US20110105541A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F ALKYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
EP3245186A1 (en) 2015-01-16 2017-11-22 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Method to prepare phenolics from biomass

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008167A1 (en) * 1991-10-24 1993-04-29 Nippon Soda Co., Ltd. Novel heterocyclic derivative and agrohorticultural bactericide containing same
AU681695B2 (en) * 1993-09-15 1997-09-04 Merck Sharp & Dohme Limited Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype ligands
JP2001139556A (ja) * 1999-03-18 2001-05-22 Nippon Soda Co Ltd インデノピリジンおよびインデノピリミジン化合物並びにその製造法
ATE293962T1 (de) * 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
WO2002085894A1 (en) * 2001-04-18 2002-10-31 Ortho-Mcneil Pharmaceutical, Inc. Arylindenopyridines with pde inhibiting activity
US6958328B2 (en) * 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods

Also Published As

Publication number Publication date
NO20061981L (no) 2006-07-03
WO2005042500A1 (en) 2005-05-12
EP1673354A1 (en) 2006-06-28
JP2007521243A (ja) 2007-08-02
CA2540686A1 (en) 2005-05-12
CY1109808T1 (el) 2014-09-10
ES2326075T3 (es) 2009-09-30
RS20060237A (en) 2008-11-28
HK1091200A1 (en) 2007-01-12
PT1673354E (pt) 2009-07-14
DK1673354T3 (da) 2009-07-27
DE60327375D1 (de) 2009-06-04
CN1878761A (zh) 2006-12-13
JP4725963B2 (ja) 2011-07-13
IL174678A0 (en) 2006-08-20
EP1673354B1 (en) 2009-04-22
ATE429421T1 (de) 2009-05-15
SI1673354T1 (sl) 2009-10-31
ECSP066474A (es) 2006-10-10
IS8377A (is) 2006-03-27
EA200600688A1 (ru) 2006-10-27
AU2003275430A1 (en) 2005-05-19
BR0318521A (pt) 2006-09-12

Similar Documents

Publication Publication Date Title
IL174678A0 (en) Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist
HK1098460A1 (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
WO2006011050A3 (en) Pyridine derivatives
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
TW200720260A (en) Prokineticin 1 receptor antagonists
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
AU2003228770A8 (en) Substituted pyrazolopyrimidines
TW200716566A (en) Prokineticin 2 receptor antagonists
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
TW200514781A (en) Novel compounds
RS20050450A (en) 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
EP1617806A4 (en) SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS
MXPA04005151A (es) Compuestos terapeuticos.
WO2003076426A3 (en) Pyridinyloxy derivatives as 5-ht receptor ligands
ATE316972T1 (de) Trizyklische crf rezeptor antagonisten
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
DK1373218T3 (da) Imidazolylderivater til anvendelse som histamin H3-receptorligander
TW200504074A (en) 7-substituted 3-nitro-pyrazolo[1,5-a]pyrimidines and compositions and methods related thereto
UA89846C2 (ru) Производные карбоксамида как антагонисты мускариновых рецепторов

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110929

Year of fee payment: 9

OBST Application withdrawn